Immunotherapy for lung cancer

Treatment of lung cancer remains a challenge, and lung cancer is still the leading cause of cancer‐related mortality. Immunotherapy has previously failed in lung cancer but has recently emerged as a very effective new therapy, and there is now growing worldwide enthusiasm in cancer immunotherapy. We...

Full description

Saved in:
Bibliographic Details
Published in:Respirology (Carlton, Vic.) Vic.), 2016-07, Vol.21 (5), p.821-833
Main Authors: Steven, Antonius, Fisher, Scott A., Robinson, Bruce W.
Format: Article
Language:English
Subjects:
antigen
antineoplastic agents
Cancer Vaccines - therapeutic use
Humans
immunotherapy
Immunotherapy - methods
lung Cancer
Lung Neoplasms - immunology
Lung Neoplasms - therapy
vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment of lung cancer remains a challenge, and lung cancer is still the leading cause of cancer‐related mortality. Immunotherapy has previously failed in lung cancer but has recently emerged as a very effective new therapy, and there is now growing worldwide enthusiasm in cancer immunotherapy. We summarize why immune checkpoint blockade therapies have generated efficacious and durable responses in clinical trials and why this has reignited interest in this field. Cancer vaccines have also been explored in the past with marginal success. Identification of optimal candidate neoantigens may improve cancer vaccine efficacy and may pave the way to personalized immunotherapy, alone or in combination with other immunotherapy such as immune checkpoint blockade. Understanding the steps in immune recognition and eradication of cancer cells is vital to understanding why previous immunotherapies failed and how current therapies can be used optimally. We hold an optimistic view for the future prospect in lung cancer immunotherapy.
ISSN:1323-7799
1440-1843
DOI:10.1111/resp.12789